The CDC’s advisory committee said there isn’t enough evidence to recommend booster shots as Pfizer reassures investors boosters will be needed long after the pandemic ends in an effort to secure its multi-billion-dollar revenue stream.
The Defender is experiencing censorship on many social channels. Be sure to stay in touch with the news that matters by subscribing to our top news of the day. It’s free.
As Pfizer makes plans to keep its billion dollar revenue stream going — by assuring investors yearly COVID booster doses will be needed long after the pandemic ends — a group of scientists from the Centers for Disease Control and Prevention (CDC) said there isn’t enough data to recommend COVID booster shots to the general population.
The COVID-19 working group of the CDC’s Advisory Committee on Immunization Practices (ACIP) said June 23, they would only recommend booster shots if there’s a demonstrated decline in efficacy –– not just a waning antibody response.
Boosters may also be recommended if there’s a variant that’s able to evade the vaccines, according to slides presented by Sara Oliver, M.D., a medical epidemiologist with CDC’s National Center for Immunization and Respiratory Diseases.
Currently, there’s no evidence to suggest a booster is needed, the experts said. Boosters may be appropriate for special risk groups in the future, including elderly people and transplant recipients. To be sure, the nation’s top public health officials said they would continue to monitor the situation.
“I would have to agree with the interpretation of the working group in the sense that there’s no data to support recommendations to support boosters at this time,” said Dr. Sharon Frey, member of the ACIP and clinical director of the Center for Vaccine Development at Saint Louis University Medical School. “There’s no evidence against declining protection at this time.”